On the public citation graph
Hormonal therapies for early breast cancer: systematic review and economic evaluation
0 signed · 183 inferred · view as graph
Inferred edges come from two machine sources: sweeps of open repository metadata (mostly SSRN and Zenodo), and a bulk OpenAlex citation snapshot. Every row below is labelled with the one it came from. Neither is a complete citation index — absence here is not evidence of absence.
Is this your work? Sign in with ORCID and put your name on the
claims that are yours.
Reference health. See whether every reference in this work resolves to a
known work and none has been retracted — and get a dated CiteStamped
badge you can embed.
What this work says
Outgoing claims: the papers this work cites, builds on, or argues with.
inferredcites →https://doi.org/10.1001/archinte.151.5.933openalex-snapshot
A population-based perspective of the hospital incidence and case-fatality rates of deep vein thrombosis and pulmonary embolism. The Worcester DVT Study
inferredcites →https://doi.org/10.1001/archinte.154.8.861openalex-snapshot
The Epidemiology of Diagnosed Pulmonary Embolism and Deep Venous Thrombosis in the Elderly
inferredcites →https://doi.org/10.1001/archinte.1991.00400050081016openalex-snapshot
A Population-Based Perspective of the Hospital Incidence and Case-Fatality Rates of Deep Vein Thrombosis and Pulmonary Embolism
inferredcites →https://doi.org/10.1001/jama.1990.03440210067034openalex-snapshot
Quality-Adjusted Life-Years
inferredcites →https://doi.org/10.1001/jama.1994.03520080061045openalex-snapshot
A Critical Appraisal of the Quality of Quality-of-Life Measurements
inferredcites →https://doi.org/10.1001/jama.273.5.408openalex-snapshot
Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials
inferredcites →https://doi.org/10.1001/jama.279.6.458openalex-snapshot
Risk of Fatal Pulmonary Embolism in Patients With Treated Venous Thromboembolism
inferredcites →https://doi.org/10.1001/jama.279.7.535openalex-snapshot
Alcohol and Breast Cancer in Women
inferredcites →https://doi.org/10.1002/1097-0142(19890101)63:1<181::aid-cncr2820630129>3.0.co;2-hopenalex-snapshot
Relation of tumor size, lymph node status, and survival in 24,740 breast cancer cases
inferredcites →https://doi.org/10.1002/14651858.cd004272.pub2openalex-snapshot
Surgery versus primary endocrine therapy for operable primary breast cancer in elderly women (70 years plus)
inferredcites →https://doi.org/10.1002/cncr.20492openalex-snapshot
Benefit and projected cost‐effectiveness of anastrozole versus tamoxifen as initial adjuvant therapy for patients with early‐stage estrogen receptor–positive breast cancer
inferredcites →https://doi.org/10.1007/978-1-4615-5195-9_25openalex-snapshot
Time-dependence of hazard ratios for prognostic factors in primary breast cancer
inferredcites →https://doi.org/10.1007/978-3-642-82982-6openalex-snapshot
TNM Classification of Malignant Tumours
inferredcites →https://doi.org/10.1007/s001980050107openalex-snapshot
The Cost of Treating Osteoporotic Fractures in the United Kingdom Female Population
inferredcites →https://doi.org/10.1016/0002-9610(80)90163-4openalex-snapshot
Breast carcinoma in the elderly patient: An assessment of operative risk, morbidity and mortality
inferredcites →https://doi.org/10.1016/0360-3016(83)90205-5openalex-snapshot
The significance of local recurrence of carcinoma of the breast
inferredcites →https://doi.org/10.1016/0378-5122(96)01038-9openalex-snapshot
A menopause-specific quality of life questionnaire: development and psychometric properties
inferredcites →https://doi.org/10.1016/j.ebobgyn.2004.04.002openalex-snapshot
Letrozole improved disease-free survival in postmenopausal women after tamoxifen treatment for breast cancer
inferredcites →https://doi.org/10.1016/s0140-6736(00)02677-5openalex-snapshot
Risk and prognosis of endometrial cancer after tamoxifen for breast cancer
inferredcites →https://doi.org/10.1016/s0140-6736(00)04337-3openalex-snapshot
The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomised trials
inferredcites →https://doi.org/10.1016/s0140-6736(02)07882-0openalex-snapshot
Sample size slippages in randomised trials: exclusions and the lost and wayward
inferredcites →https://doi.org/10.1016/s0140-6736(02)09088-8openalex-snapshot
Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial
inferredcites →https://doi.org/10.1016/s0140-6736(05)66544-0openalex-snapshot
Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials
inferredcites →https://doi.org/10.1016/s0140-6736(05)67059-6openalex-snapshot
Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial
inferredcites →https://doi.org/10.1016/s0140-6736(99)04149-5openalex-snapshot
Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement
inferredcites →https://doi.org/10.1016/s0360-3016(01)01625-xopenalex-snapshot
Long-term results of local recurrence after breast conservation treatment for invasive breast cancer
inferredcites →https://doi.org/10.1016/s0360-3016(99)00428-9openalex-snapshot
Locoregional first recurrence after mastectomy: prospective cohort studies with and without immediate chemotherapy
inferredcites →https://doi.org/10.1016/s0378-5122(96)82006-8openalex-snapshot
A menopause-specific quality of life questionnaire: development and psychometric properties
inferredcites →https://doi.org/10.1016/s0960-0760(03)00350-9openalex-snapshot
‘Arimidex’ (anastrozole) versus tamoxifen as adjuvant therapy in postmenopausal women with early breast cancer-efficacy overview
inferredcites →https://doi.org/10.1016/s0960-9776(03)80136-4openalex-snapshot
Assessing the quality of life of postmenopausal women randomized into the ATAC (“arimidex”, tamoxifen, alone or in combination) adjuvant breast cancer trial
inferredcites →https://doi.org/10.1016/s0960-9776(03)80145-5openalex-snapshot
Phase III randomized adjuvant study of tamoxifen alone versus sequential tamoxifen and anastrozole in hormone-responsive postmenopausal breast cancer patients (National Surgical Adjuvant Study of Breast Cancer [NSAS BC] 03)
inferredcites →https://doi.org/10.1016/s1040-8428(99)00023-2openalex-snapshot
Costs of palliative care in the community, in hospitals and in hospices in the UK
inferredcites →https://doi.org/10.1016/s1043-321x(05)80236-xopenalex-snapshot
3–38 Quality of Life of Postmenopausal Women in the Arimidex, Tamoxifen, Alone or in Combination (ATAC) Adjuvant Breast Cancer Trial
inferredcites →https://doi.org/10.1016/s1043-321x(05)80250-4openalex-snapshot
3–42 Cost of Managing Women Presenting With Stage IV Breast Cancer in the United Kingdom
inferredcites →https://doi.org/10.1016/s1043-321x(06)80543-6openalex-snapshot
Randomized Trial of Letrozole Following Tamoxifen as Extended Adjuvant Therapy in Receptor-Positive Breast Cancer: Updated Findings From NCIC CTG MA.17
inferredcites →https://doi.org/10.1016/s1470-0328(03)02920-3openalex-snapshot
The ATAC adjuvant breast cancer trial in postmenopausal women: baseline endometrial subprotocol data
inferredcites →https://doi.org/10.1016/s1526-8209(11)70424-4openalex-snapshot
Anastrozole May Be Superior to Tamoxifen as Adjuvant Treatment for Postmenopausal Patients with Breast Cancer
inferredcites →https://doi.org/10.1016/s1526-8209(11)70943-0openalex-snapshot
A Benefit of Letrozole in Postmenopausal Women After Five Years of Tamoxifen Therapy for Early-Stage Breast Cancer
inferredcites →https://doi.org/10.1023/a:1005845100512openalex-snapshot
Pattern of dissemination and survival following isolated locoregional recurrence of breast cancer
inferredcites →https://doi.org/10.1023/a:1006133418245openalex-snapshot
Time-dependence of hazard ratios for prognostic factors in primary breast cancer
inferredcites →https://doi.org/10.1023/a:1006263818115openalex-snapshot
Assessment of quality of life in women undergoing hormonal therapy for breast cancer: validation of an endocrine symptom subscale for the FACT‐B
inferredcites →https://doi.org/10.1038/sj.bjc.6601742openalex-snapshot
Stage and treatment variation with age in postmenopausal women with breast cancer: compliance with guidelines
inferredcites →https://doi.org/10.1046/j.1365-2168.2000.01534.xopenalex-snapshot
Effect of surgical subspecialization on breast cancer outcome
inferredcites →https://doi.org/10.1046/j.1524-4741.2002.08202.xopenalex-snapshot
Local-Regional Breast Cancer Recurrence: Prognostic Groups Based on Patterns of Failure
inferredcites →https://doi.org/10.1053/ctrv.1999.0161openalex-snapshot
Systematic reviews of chemotherapy and endocrine therapy in metastatic breast cancer
inferredcites →https://doi.org/10.1056/nejmoa032312openalex-snapshot
A Randomized Trial of Letrozole in Postmenopausal Women after Five Years of Tamoxifen Therapy for Early-Stage Breast Cancer
inferredcites →https://doi.org/10.1089/blr.2007.9941openalex-snapshot
Guidance for Industry: Clinical Trial Endpoints for the Approval of Cancer Drugs and Biologics
inferredcites →https://doi.org/10.1093/annonc/mdi021openalex-snapshot
Third generation aromatase inhibitors may prevent endometrial growth and reverse tamoxifen-induced uterine changes in postmenopausal breast cancer patients
inferredcites →https://doi.org/10.1093/jnci/85.17.1398openalex-snapshot
Cardiac and Thromboembolic Morbidity Among Postmenopausal Women With Early Stage Breast Cancer in a Randomized Trial of Adjuvant Tamoxifen
inferredcites →https://doi.org/10.1093/jnci/86.20.1534openalex-snapshot
Effects of Tamoxifen on Cardiovascular Risk Factors in Postmenopausal Women After 5 Years of Treatment
inferredcites →https://doi.org/10.1093/jnci/90.18.1371openalex-snapshot
Tamoxifen for Prevention of Breast Cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study
inferredcites →https://doi.org/10.1093/jnci/95.23.1738openalex-snapshot
Critics Question Price of Success in Halted Clinical Trial of Aromatase Inhibitor Letrozole
inferredcites →https://doi.org/10.1093/jnci/dji250openalex-snapshot
Randomized Trial of Letrozole Following Tamoxifen as Extended Adjuvant Therapy in Receptor-Positive Breast Cancer: Updated Findings from NCIC CTG MA.17
inferredcites →https://doi.org/10.1093/jnci/dji342openalex-snapshot
Coronary Heart Disease Mortality After 5 Years of Adjuvant Tamoxifen Therapy: Results from a Randomized Trial
inferredcites →https://doi.org/10.1097/00005650-200006000-00004openalex-snapshot
One Thousand Health-Related Quality-of-Life Estimates
inferredcites →https://doi.org/10.1097/00006254-197602000-00017openalex-snapshot
PREDICTING RESPONSE TO ENDOCRINE THERAPY IN HUMAN BREAST CANCER
inferredcites →https://doi.org/10.1097/00006254-200102000-00018openalex-snapshot
Risk and Prognosis of Endometrial Cancer After Tamoxifen for Breast Cancer
inferredcites →https://doi.org/10.1097/00006254-200109000-00019openalex-snapshot
Tamoxifen and Cardiac Risk Factors in Healthy Women: Suggestion of an Anti-Inflammatory Effect
inferredcites →https://doi.org/10.1097/00006534-198911000-00055openalex-snapshot
Relation of tumor size, lymph node status, and survival in 24,740 breast cancer cases
inferredcites →https://doi.org/10.1097/01.ogx.0000115858.45890.53openalex-snapshot
A Randomized Trial of Letrozole in Postmenopausal Women After Five Years of Tamoxifen Therapy for Early-Stage Breast Cancer
inferredcites →https://doi.org/10.1097/01.ogx.0000160573.78426.6aopenalex-snapshot
Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) Trial After Completion of 5 Years??? Adjuvant Treatment for Breast Cancer
inferredcites →https://doi.org/10.1136/bmj.308.6930.714aopenalex-snapshot
Management of breast cancer Refer women to multidisciplinary breast clinics
inferredcites →https://doi.org/10.1136/bmj.319.7223.1492openalex-snapshot
Calculating the number needed to treat for trials where the outcome is time to an event
inferredcites →https://doi.org/10.1136/bmj.320.7239.884openalex-snapshot
Cancer trends in England and Wales
inferredcites →https://doi.org/10.1136/bmj.321.7275.1527/aopenalex-snapshot
Effect of screening programme on mortality from breast cancer
inferredcites →https://doi.org/10.1136/bmj.326.7382.219openalex-snapshot
Interaction revisited: the difference between two estimates
inferredcites →https://doi.org/10.1136/bmj.38414.422650.8fopenalex-snapshot
Comparison of descriptions of allocation concealment in trial protocols and the published reports: cohort study
inferredcites →https://doi.org/10.1159/000055014openalex-snapshot
Improving the Quality of Reports of Meta-Analyses of Randomised Controlled Trials: The QUOROM Statement
inferredcites →https://doi.org/10.1161/01.str.21.6.848openalex-snapshot
Prognosis of transient ischemic attacks in the Oxfordshire Community Stroke Project.
inferredcites →https://doi.org/10.1186/1477-7819-3-17openalex-snapshot
Optimising surgical management of elderly cancer patients
inferredcites →https://doi.org/10.1200/jco.1993.11.1.44openalex-snapshot
Prognosis following salvage mastectomy for recurrence in the breast after conservative surgery and radiation therapy for early-stage breast cancer.
inferredcites →https://doi.org/10.1200/jco.1993.11.3.570openalex-snapshot
The Functional Assessment of Cancer Therapy scale: development and validation of the general measure.
inferredcites →https://doi.org/10.1200/jco.1996.14.10.2738openalex-snapshot
Annual hazard rates of recurrence for breast cancer after primary therapy.
inferredcites →https://doi.org/10.1200/jco.1997.15.3.974openalex-snapshot
Reliability and validity of the Functional Assessment of Cancer Therapy-Breast quality-of-life instrument.
inferredcites →https://doi.org/10.1200/jco.2000.18.8.1696openalex-snapshot
Role of Isolated Locoregional Recurrence of Breast Cancer: Results of Four Prospective Studies
inferredcites →https://doi.org/10.1200/jco.2003.01.138openalex-snapshot
Randomized Trial of Tamoxifen Versus Tamoxifen Plus Aminoglutethimide as Adjuvant Treatment in Postmenopausal Breast Cancer Patients With Hormone Receptor-Positive Disease: Austrian Breast and Colorectal Cancer Study Group Trial 6
inferredcites →https://doi.org/10.1200/jco.2003.09.099openalex-snapshot
Progesterone Receptor Status Significantly Improves Outcome Prediction Over Estrogen Receptor Status Alone for Adjuvant Endocrine Therapy in Two Large Breast Cancer Databases
inferredcites →https://doi.org/10.1200/jco.2004.22.14_suppl.516openalex-snapshot
A planned comparison of menopausal symptoms during the first year in 1,000 patients receiving either exemestane or tamoxifen in a double-blind adjuvant hormonal study
inferredcites →https://doi.org/10.1200/jco.2004.22.14_suppl.799openalex-snapshot
The effect of exemestane on the lipidemic profile of breast cancer patients: Preliminary results of the TEAM trial Greek sub-study
inferredcites →https://doi.org/10.1200/jco.2004.22.14_suppl.847openalex-snapshot
Updated analysis of the NCIC CTG MA.17 randomized placebo (P) controlled trial of letrozole (L) after five years of tamoxifen in postmenopausal women with early stage breast cancer
inferredcites →https://doi.org/10.1200/jco.2005.04.120openalex-snapshot
Switching to Anastrozole Versus Continued Tamoxifen Treatment of Early Breast Cancer: Preliminary Results of the Italian Tamoxifen Anastrozole Trial
inferredcites →https://doi.org/10.1200/jco.2005.09.121openalex-snapshot
American Society of Clinical Oncology Technology Assessment on the Use of Aromatase Inhibitors As Adjuvant Therapy for Postmenopausal Women With Hormone Receptor–Positive Breast Cancer: Status Report 2004
inferredcites →https://doi.org/10.1200/jco.2005.11.181openalex-snapshot
Assessment of Quality of Life in MA.17: A Randomized, Placebo-Controlled Trial of Letrozole After 5 Years of Tamoxifen in Postmenopausal Women
inferredcites →https://doi.org/10.1200/jco.2005.23.16_suppl.511openalex-snapshot
BIG 1–98: Randomized double-blind phase III study to evaluate letrozole (L) vs. tamoxifen (T) as adjuvant endocrine therapy for postmenopausal women with receptor-positive breast cancer
inferredcites →https://doi.org/10.1200/jco.2005.23.16_suppl.526openalex-snapshot
Switching to anastrozole (ANA) vs continued tamoxifen (TAM) treatment of early breast cancer (EBC). Updated results of the Italian tamoxifen anastrozole (ITA) trial
inferredcites →https://doi.org/10.1200/jco.2005.23.16_suppl.527openalex-snapshot
Extended adjuvant treatment with anastrozole: Results from the Austrian Breast and Colorectal Cancer Study Group Trial 6a (ABCSG-6a)
inferredcites →https://doi.org/10.1200/jco.2005.23.16_suppl.577openalex-snapshot
Five-year quality of life (QOL) follow-up of adjuvant endocrine therapy for postmenopausal women in the Arimidex (A), Tamoxifen (T), Alone or in Combination (ATAC) Trial
inferredcites →https://doi.org/10.1200/jco.2005.23.16_suppl.582openalex-snapshot
Using anastrozole as initial adjuvant treatment prevents early recurrences and reduces adverse events: Updated data from the ATAC (‘Arimidex’, Tamoxifen, Alone or in Combination) trial
inferredcites →https://doi.org/10.1200/jco.2005.23.16_suppl.612openalex-snapshot
An exploration of relapse data by hazard rate as a means of developing biological insights into the natural history and treatment of breast cancer: Data from the ’Arimidex’, Tamoxifen, Alone or in Combination (ATAC) trial and the Milan Institute database
inferredcites →https://doi.org/10.1200/jco.22.02775openalex-snapshot
The Functional Assessment of Cancer Therapy Scale: Development and Validation of the General Measure
inferredcites →https://doi.org/10.1210/jc.80.11.3191openalex-snapshot
The effect of the anti-estrogen tamoxifen on cardiovascular risk factors in normal postmenopausal women
inferredcites →https://doi.org/10.1210/jcem.80.11.7593425openalex-snapshot
The effect of the anti-estrogen tamoxifen on cardiovascular risk factors in normal postmenopausal women.
inferredcites →https://doi.org/10.1615/critrevoncog.v8.i2-3.40openalex-snapshot
Physical Activity and Cancer: How May Protection Be Maximized?
inferredcites →https://doi.org/10.1677/erc.0.0060075openalex-snapshot
Use of aromatase inhibitors in breast carcinoma.
inferredcites →https://doi.org/10.2165/00003495-199958020-00003openalex-snapshot
Comprehensive Pharmacology and Clinical Efficacy of Aromatase Inhibitors
inferredcites →https://doi.org/10.3109/14733400500033540openalex-snapshot
Breast surgery in the ‘Arimidex, Tamoxifen alone or in combination’ (ATAC) trial: American women are more likely than women from the United Kingdom to undergo mastectomy
inferredcites →https://doi.org/10.3310/hta10150openalex-snapshot
Measurement of the clinical and cost-effectiveness of non-invasive diagnostic testing strategies for deep vein thrombosis
inferredcites →https://doi.org/10.3310/hta6290openalex-snapshot
Treatment of established osteoporosis: a systematic review and cost-utility analysis
inferredcites →https://doi.org/10.3322/canjclin.55.3.145openalex-snapshot
Aromatase Inhibitors as Adjuvant Therapy for Postmenopausal Patients With Early Stage Breast Cancer
inferredcites →https://doi.org/10.3816/cbc.2003.s.014openalex-snapshot
Anastrozole as Adjuvant Therapy for Early-Stage Breast Cancer: Implications of the ATAC Trial
inferredcites →https://doi.org/10.5858/2000-124-0966-pfibcopenalex-snapshot
Prognostic factors in breast cancer. College of American Pathologists Consensus Statement 1999.
inferredcites →https://doi.org/10.7326/0003-4819-120-2-199401150-00002openalex-snapshot
The Effect of Comorbidity on 3-Year Survival of Women with Primary Breast Cancer
inferredcites →https://doi.org/10.7748/nm.8.2.39.s15openalex-snapshot
The National Institute for Clinical Excellence
What points at this work
Incoming claims: where this work appears in other papers’ reference lists and arguments.
inferred← citeshttps://doi.org/10.3897/pharmacia.71.e135324zenodo-depositor-declared
Health-related quality of life outcomes between non-steroid and steroid aromatase inhibitors and switching hormone therapy in postmenopausal women with ER+ breast cancer
inferred← citeshttps://doi.org/10.1002/pon.1860openalex-snapshot
Cognitive limitations associated with tamoxifen and aromatase inhibitors in employed breast cancer survivors
inferred← citeshttps://doi.org/10.1007/978-3-319-56673-3_44openalex-snapshot
Breast Cancer in Older Patients
inferred← citeshttps://doi.org/10.1007/s00216-010-4075-zopenalex-snapshot
Development and validation of a liquid chromatography–tandem mass spectrometry method for the simultaneous quantification of tamoxifen, anastrozole, and letrozole in human plasma and its application to a clinical study
inferred← citeshttps://doi.org/10.1007/s00408-012-9445-1openalex-snapshot
Management of Malignant Pleural Effusion
inferred← citeshttps://doi.org/10.1007/s00432-010-0942-4openalex-snapshot
Assessing the efficacy of targeted therapy using circulating epithelial tumor cells (CETC): the example of SERM therapy monitoring as a unique tool to individualize therapy
inferred← citeshttps://doi.org/10.1007/s10549-015-3309-3openalex-snapshot
Cost-effectiveness of prophylactic granulocyte colony-stimulating factor for febrile neutropenia in breast cancer patients receiving FEC-D
inferred← citeshttps://doi.org/10.1007/s10549-015-3382-7openalex-snapshot
Hepatitis B virus screening before adjuvant chemotherapy in patients with early-stage breast cancer: a cost-effectiveness analysis
inferred← citeshttps://doi.org/10.1007/s10549-017-4374-6openalex-snapshot
Reviewing the quality, health benefit and value for money of chemotherapy and targeted therapy for metastatic breast cancer
inferred← citeshttps://doi.org/10.1007/s10926-015-9576-3openalex-snapshot
Validation of the Chinese Version of the Cognitive Symptom Checklist-Work-21 in Breast Cancer Survivors
inferred← citeshttps://doi.org/10.1007/s12325-011-0075-4openalex-snapshot
An Overview of Letrozole in Postmenopausal Women with Hormone-Responsive Breast Cancer
inferred← citeshttps://doi.org/10.1007/s12609-017-0238-7openalex-snapshot
New Guidelines on the Adequacy of Lumpectomy Margin Width in Patients with Ductal Carcinoma In Situ
inferred← citeshttps://doi.org/10.1007/s40273-013-0106-xopenalex-snapshot
The Impact of Structural Uncertainty on Cost-Effectiveness Models for Adjuvant Endocrine Breast Cancer Treatments: the Need for Disease-Specific Model Standardization and Improved Guidance
inferred← citeshttps://doi.org/10.1007/s40273-014-0227-xopenalex-snapshot
Cost-Effectiveness Analysis of Prognostic Gene Expression Signature-Based Stratification of Early Breast Cancer Patients
inferred← citeshttps://doi.org/10.1007/s40487-018-0062-xopenalex-snapshot
Endocrine Therapy for Breast Cancer: A Model of Hormonal Manipulation
inferred← citeshttps://doi.org/10.1016/b978-1-4160-6231-8.10094-7openalex-snapshot
Geriatric Oncology
inferred← citeshttps://doi.org/10.1016/j.bjpt.2018.12.003openalex-snapshot
Explaining pain following cancer: a practical guide for clinicians
inferred← citeshttps://doi.org/10.1016/j.breastdis.2014.10.034openalex-snapshot
Are Margins Bigger Than “No Ink on Tumor” Better? Decidedly Not!
inferred← citeshttps://doi.org/10.1016/j.ctarc.2021.100358openalex-snapshot
Appraising the quality of meta-analysis for breast cancer treatment in the adjuvant setting: A systematic review
inferred← citeshttps://doi.org/10.1016/j.ctarc.2022.100578openalex-snapshot
The analysis of breast cancer survival in East Azerbaijan province of Iran; prognostic impact of chemotherapy and hormone therapy protocols
inferred← citeshttps://doi.org/10.1016/j.ejca.2006.08.010openalex-snapshot
Methodological issues in the economic analysis of cancer treatments
inferred← citeshttps://doi.org/10.1016/j.ejca.2008.03.010openalex-snapshot
Recent trends in cancer survival across Europe between 2000 and 2004: A model-based period analysis from 12 cancer registries
inferred← citeshttps://doi.org/10.1016/j.ijrobp.2013.11.012openalex-snapshot
Society of Surgical Oncology–American Society for Radiation Oncology Consensus Guideline on Margins for Breast-Conserving Surgery With Whole-Breast Irradiation in Stages I and II Invasive Breast Cancer
inferred← citeshttps://doi.org/10.1016/j.ijrobp.2018.03.005openalex-snapshot
Close Margins Less Than 2 mm Are Not Associated With Higher Risks of 10-Year Local Recurrence and Breast Cancer Mortality Compared With Negative Margins in Women Treated With Breast-Conserving Therapy
inferred← citeshttps://doi.org/10.1016/j.jmwh.2007.12.013openalex-snapshot
Current Resources for Evidence‐Based Practice, March/April 2008
inferred← citeshttps://doi.org/10.1016/j.jval.2010.10.037openalex-snapshot
Cost-Effectiveness of Granulocyte Colony–Stimulating Factor Prophylaxis for Febrile Neutropenia in Breast Cancer in the United Kingdom
inferred← citeshttps://doi.org/10.1016/j.jval.2011.01.008openalex-snapshot
Survival Time Outcomes in Randomized, Controlled Trials and Meta-Analyses: The Parallel Universes of Efficacy and Cost-Effectiveness
inferred← citeshttps://doi.org/10.1016/j.jval.2011.05.048openalex-snapshot
Prioritizing Pharmacogenetic Research: A Value of Information Analysis of CYP2D6 Testing to Guide Breast Cancer Treatment
inferred← citeshttps://doi.org/10.1016/j.jval.2021.03.008openalex-snapshot
Comparison of Parametric Survival Extrapolation Approaches Incorporating General Population Mortality for Adequate Health Technology Assessment of New Oncology Drugs
inferred← citeshttps://doi.org/10.1016/j.radonc.2008.05.002openalex-snapshot
Local relapse rates are falling after breast conserving surgery and systemic therapy for early breast cancer: Can radiotherapy ever be safely withheld?
inferred← citeshttps://doi.org/10.1016/j.suronc.2014.11.006openalex-snapshot
Lumpectomy margins: Everything old is new again?
inferred← citeshttps://doi.org/10.1016/s0140-6736(08)60706-0openalex-snapshot
Trastuzumab: possible publication bias
inferred← citeshttps://doi.org/10.1017/s1357321713000184openalex-snapshot
Cancer survival extension from drug treatments
inferred← citeshttps://doi.org/10.1038/bjc.2013.207openalex-snapshot
A decision impact, decision conflict and economic assessment of routine Oncotype DX testing of 146 women with node-negative or pNImi, ER-positive breast cancer in the UK
inferred← citeshttps://doi.org/10.1038/s41571-021-00584-zopenalex-snapshot
The value of anticancer drugs — a regulatory view
inferred← citeshttps://doi.org/10.1055/s-0031-1280435openalex-snapshot
Health Services Research and Health Economy – Quality Care Training in Gynaecology, with Focus On Gynaecological Oncology
inferred← citeshttps://doi.org/10.1080/09638288.2016.1261418openalex-snapshot
Treatment of pain following cancer: applying neuro-immunology in rehabilitation practice
inferred← citeshttps://doi.org/10.1089/jwh.2009.1831openalex-snapshot
Implications of Mobility Impairment on the Diagnosis and Treatment of Breast Cancer
inferred← citeshttps://doi.org/10.1093/annonc/mdn639openalex-snapshot
Trends in cancer survival in 11 European populations from 1990 to 2009: a model-based analysis
inferred← citeshttps://doi.org/10.1111/ecc.12601openalex-snapshot
Factors associated with intentional and unintentional non-adherence to adjuvant endocrine therapy following breast cancer
inferred← citeshttps://doi.org/10.1111/j.1524-4741.2009.00696.xopenalex-snapshot
Enhancing the Adjuvant Treatment of Hormone Receptor Positive Breast Cancer
inferred← citeshttps://doi.org/10.1111/j.1742-1241.2007.01603.xopenalex-snapshot
Choices and challenges in endocrine treatment for breast cancer
inferred← citeshttps://doi.org/10.1159/000286233openalex-snapshot
Cost-Effectiveness Analysis of Anastrozole versus Tamoxifen in Adjuvant Therapy for Early-Stage Breast Cancer – A Health-Economic Analysis Based on the 100-Month Analysis of the ATAC Trial and the German Health System
inferred← citeshttps://doi.org/10.1159/000333118openalex-snapshot
Cost-Benefit Analysis of Endocrine Therapy in the Adjuvant Setting for Postmenopausal Patients with Hormone Receptor-Positive Breast Cancer, Based on Survival Data and Future Prices for Generic Drugs in the Context of the German Health Care System
inferred← citeshttps://doi.org/10.11606/t.5.2010.tde-01022011-161711openalex-snapshot
Comparação dos resultados de marcadores prognósticos e preditivos (HER2 e receptores de estrógeno e progesterona) para carcinoma de mama entre laboratórios locais e de referência no Brasil
inferred← citeshttps://doi.org/10.1177/0272989x14539731openalex-snapshot
Opportunity Cost of Funding Drugs for Rare Diseases
inferred← citeshttps://doi.org/10.1177/0272989x16639900openalex-snapshot
Extrapolating Survival from Randomized Trials Using External Data: A Review of Methods
inferred← citeshttps://doi.org/10.1177/1534735415596573openalex-snapshot
Acupuncture for Aromatase Inhibitor–Induced Arthralgia
inferred← citeshttps://doi.org/10.1186/s12955-022-02067-wopenalex-snapshot
The impact of age on health utility values for older women with early-stage breast cancer: a systematic review and meta-regression
inferred← citeshttps://doi.org/10.1200/jco.2009.26.3756openalex-snapshot
American Society of Clinical Oncology Clinical Practice Guideline: Update on Adjuvant Endocrine Therapy for Women With Hormone Receptor–Positive Breast Cancer
inferred← citeshttps://doi.org/10.1200/jco.2013.53.3935openalex-snapshot
Society of Surgical Oncology–American Society for Radiation Oncology Consensus Guideline on Margins for Breast-Conserving Surgery With Whole-Breast Irradiation in Stages I and II Invasive Breast Cancer
inferred← citeshttps://doi.org/10.1245/s10434-014-3481-4openalex-snapshot
Society of Surgical Oncology–American Society for Radiation Oncology Consensus Guideline on Margins for Breast-Conserving Surgery With Whole-Breast Irradiation in Stages I and II Invasive Breast Cancer
inferred← citeshttps://doi.org/10.1371/journal.pone.0062614openalex-snapshot
A Systematic Review and Methodological Evaluation of Published Cost-Effectiveness Analyses of Aromatase Inhibitors versus Tamoxifen in Early Stage Breast Cancer
inferred← citeshttps://doi.org/10.15204/jkobgy.2014.27.2.012openalex-snapshot
Effects of Cuscutae Semen Water Extract on Apoptosis of MCF-7 Human Breast Cancer Cells
inferred← citeshttps://doi.org/10.15204/jkobgy.2015.28.2.040openalex-snapshot
Effects of Citri Reticulatae Viride Pericarpium on the Apoptotic Cell Death in Breast Cancer Cells
inferred← citeshttps://doi.org/10.1530/erc-10-0162openalex-snapshot
A critical evaluation of the role of aromatase inhibitors as adjuvant therapy for postmenopausal women with breast cancer
inferred← citeshttps://doi.org/10.1586/14737167.7.2.143openalex-snapshot
Cost–effectiveness of letrozole, anastrozole and exemestane for early adjuvant breast cancer
inferred← citeshttps://doi.org/10.1586/erp.10.65openalex-snapshot
Health-state utility values in breast cancer
inferred← citeshttps://doi.org/10.21236/ad1012868openalex-snapshot
Development of the Cancer Survivor Profile
inferred← citeshttps://doi.org/10.2146/ajhp100492openalex-snapshot
Clinical and economic benefits of aromatase inhibitor therapy in early-stage breast cancer
inferred← citeshttps://doi.org/10.2147/ceor.s4220openalex-snapshot
Pharmacoeconomic considerations in the treatment of breast cancer
inferred← citeshttps://doi.org/10.2165/00019053-200826050-00005openalex-snapshot
Methodological Issues in Evaluating Cost Effectiveness of Adjuvant Aromatase Inhibitors in Early Breast Cancer
inferred← citeshttps://doi.org/10.26481/dis.20201127xpopenalex-snapshot
Embracing uncertainty in health technology assessment
inferred← citeshttps://doi.org/10.3310/hta11400openalex-snapshot
Taxanes for the adjuvant treatment of early breast cancer: systematic review and economic evaluation
inferred← citeshttps://doi.org/10.3310/hta13620openalex-snapshot
Are adverse effects incorporated in economic models? An initial review of current practice
inferred← citeshttps://doi.org/10.3310/hta15040openalex-snapshot
Positron emission tomography (PET) and magnetic resonance imaging (MRI) for the assessment of axillary lymph node metastases in early breast cancer: systematic review and economic evaluation
inferred← citeshttps://doi.org/10.3310/hta15330openalex-snapshot
The clinical effectiveness and cost-effectiveness of genotyping for CYP2D6 for the management of women with breast cancer treated with tamoxifen: a systematic review.
inferred← citeshttps://doi.org/10.3310/hta17440openalex-snapshot
Gene expression profiling and expanded immunohistochemistry tests to guide the use of adjuvant chemotherapy in breast cancer management: a systematic review and cost-effectiveness analysis
inferred← citeshttps://doi.org/10.3310/hta19690openalex-snapshot
The INTRABEAM® Photon Radiotherapy System for the adjuvant treatment of early breast cancer: a systematic review and economic evaluation
inferred← citeshttps://doi.org/10.3310/hta20730openalex-snapshot
An international randomised controlled trial to compare TARGeted Intraoperative radioTherapy (TARGIT) with conventional postoperative radiotherapy after breast-conserving surgery for women with early-stage breast cancer (the TARGIT-A trial)
inferred← citeshttps://doi.org/10.3310/xzoe2552openalex-snapshot
Improving outcomes for women aged 70 years or above with early breast cancer: research programme including a cluster RCT
inferred← citeshttps://doi.org/10.3322/ca.2008.0008openalex-snapshot
Economic Evaluations of Medical Care Interventions for Cancer Patients: How, Why, and What Does it Mean?
inferred← citeshttps://doi.org/10.4048/jbc.2010.13.3.286openalex-snapshot
Cost-Effectiveness Analysis of Adjuvant Hormonal Treatments for Women with Postmenopausal Hormone-Receptor Positive Early Breast Cancer in the Korean Context
inferred← citeshttps://doi.org/10.4137/bcbcr.s6234openalex-snapshot
Exemestane in the Adjuvant Treatment of Breast Cancer in Postmenopausal Women
inferred← citeshttps://doi.org/10.4137/cmwh.s8692openalex-snapshot
Clinical Utility of Aromatase Inhibitors as Adjuvant Treatment in postmenopausal Early Breast Cancer
inferred← citeshttps://doi.org/10.47749/t/unicamp.2016.967681openalex-snapshot
Segurança no uso de medicamentos em unidade de internação oncológica especializada na saúde da mulher
inferred← citeshttps://doi.org/10.5772/25293openalex-snapshot
Breast Cancer: Radioimmunoscintigraphy and Radioimmunotherapy
inferred← citeshttps://doi.org/10.5897/jcreo11.046openalex-snapshot
Levonorgestrel-releasing intrauterine device for management of tamoxifen-induced menorrhagia in breast cancer patients
Editorial review for independent work. ICSAC — the Institute for Complexity
Science and Advanced Computing — runs a structured editorial panel for researchers
publishing outside journals, and publishes on CiteStamp rails. Submission is free
and goes through ORCID: icsacinstitute.org/submit.